Drug intelligence / Profile preview

GEP-1

Development stage
Preclinical
Modality
Peptides
Administration
Oral
01

Overview

GEP-1 is a research designation used for two distinct biological substances identified in natural product research. Most commonly, it refers to a water-soluble polysaccharide isolated from the rhizome of *Gastrodia elata* Blume (Tianma). This polysaccharide is primarily an α-(1→4)-glucan composed of glucose units, with reported molecular weights ranging from approximately 3.7 kDa to 76 kDa. It exhibits neuroprotective effects against heavy metal-induced oxidative stress, immunomodulatory activity via the activation of the NF-κB signaling pathway, and prebiotic potential by modulating gut microbiota. Separately, GEP-1 also refers to a cyclic peptide [cyclic-(Trp-Leu-His-Val)] isolated from *Gelsemium elegans*. This peptide has demonstrated anti-tumor activity in cervical carcinoma models by inducing apoptosis through both intrinsic (mitochondrial) and extrinsic (Fas/FADD-mediated) pathways.

Other names
Gastrodia elata polysaccharide 1Gelsemium elegans cyclic peptide 1cyclic-(Trp-Leu-His-Val)-peptide
02

Targets

TNFRSF (TNF receptor superfamily)

Beyond the preview

Go deeper on GEP-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on GEP-1.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call